Insider · CIK 0001539937
Jack A. Khattar
ceopresidentofficerdirector
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.), CGTX (COGNITION THERAPEUTICS INC), SCPH (scPharmaceuticals Inc.). First filing Nov 8, 2024, latest Mar 16, 2026.
In brief
Jack A. Khattar files SEC Form 4 as CEO, president and director at SUPN (SUPERNUS PHARMACEUTICALS, INC.), and also at CGTX (COGNITION THERAPEUTICS INC), SCPH (scPharmaceuticals Inc.). Since Nov 8, 2024, Jack A. Khattar has reported 0 open-market buys worth $0 and 16 open-market sells worth $29M, the latest filed on Mar 16, 2026.
A track record needs three past buys with six months of prices behind them; Jack A. Khattar has 0, so none is measured yet.
The newest scored trade: sold $1.8M of SUPN on Mar 13, 2026, filed Mar 16, 2026, scored 45 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $1.8M.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 16
$0 bought, $29M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
SUPNOct 9, 2026 · close 42.67
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | SUPERNUS PHARMACEUTICALS, INC. | $1.8M 35,000 shares | -4% | +65% from low-12% from high | |
| 23Weak | SUPERNUS PHARMACEUTICALS, INC. | $3.0M 59,900 shares | -5% | +63% from low0% from high | |
| 7Weak | SUPERNUS PHARMACEUTICALS, INC. | $92k 1,904 shares | -0% | +58% from low-0% from high | |
| 23Weak | SUPERNUS PHARMACEUTICALS, INC. | $1.9M 40,173 shares | -3% | +59% from low0% from high | |
| 14Weak | SUPERNUS PHARMACEUTICALS, INC. | $414k 8,588 shares | -1% | +58% from low0% from high | |
| 16Weak | SUPERNUS PHARMACEUTICALS, INC. | $491k 10,235 shares | -1% | +57% from low0% from high | |
| 23Weak | SUPERNUS PHARMACEUTICALS, INC. | $1.4M 29,513 shares | -3% | +56% from low-0% from high | |
| 20Weak | SUPERNUS PHARMACEUTICALS, INC. | $780k 16,587 shares | -1% | +57% from low0% from high | |
| 19Weak | SUPERNUS PHARMACEUTICALS, INC. | $293k 6,322 shares | -1% | +53% from low-0% from high | |
| 30Weak | SUPERNUS PHARMACEUTICALS, INC. | $2.6M 55,578 shares | -5% | +54% from low0% from high | |
| 30Weak | SUPERNUS PHARMACEUTICALS, INC. | $1.6M 34,800 shares | -3% | +51% from low0% from high | |
| 11Weak | SUPERNUS PHARMACEUTICALS, INC. | $45k 1,000 shares | -0% | +48% from low-1% from high | |
| 13Weak | SUPERNUS PHARMACEUTICALS, INC. | $68k 1,500 shares | -0% | +50% from low0% from high | |
| 35Weak | SUPERNUS PHARMACEUTICALS, INC. | $5.9M 140,000 shares | -13% | +42% from low0% from high | |
| 55Moderate | SUPERNUS PHARMACEUTICALS, INC. | $4.5M 125,000 shares | -12% | - | |
| 55Moderate | SUPERNUS PHARMACEUTICALS, INC. | $4.6M 125,000 shares | -12% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 13, 2026 | SUPN SUPERNUS PHARMACEUTICALS INC | 35,000 0.06% of outstanding | $1.8M | Mar 13, 2026 | none |
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 59,900 0.11% of outstanding | $2.9M | Oct 9, 2025 | $16M |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 1,904 0.00% of outstanding | $91k | Oct 2, 2025 | $15M |
| Oct 1, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 40,173 0.07% of outstanding | $1.9M | Oct 1, 2025 | $13M |
| Sep 30, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 8,588 0.02% of outstanding | $409k | Sep 30, 2025 | $13M |
| Sep 29, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 10,235 0.02% of outstanding | $481k | Sep 29, 2025 | $13M |
| Sep 23, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 29,513 0.05% of outstanding | $1.4M | Sep 23, 2025 | $11M |
| Sep 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 16,587 0.03% of outstanding | $764k | Sep 22, 2025 | $10M |
| Sep 8, 2025 | SUPN Supernus Pharmaceuticals, Inc. | 6,322 0.01% of outstanding | $291k | Sep 8, 2025 | $10M |
| Sep 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 55,578 0.10% of outstanding | $2.5M | Sep 5, 2025 | $7.6M |
| Aug 28, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 24,150 0.04% of outstanding | $1.1M | Aug 28, 2025 | $6.5M |
| Aug 27, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 10,650 0.02% of outstanding | $472k | Aug 27, 2025 | $6.0M |
| Aug 25, 2025 | SUPN SUPERNUS PHARMACEUTICALS INC | 1,000 0.00% of outstanding | $45k | Aug 25, 2025 | $6.0M |
| Aug 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS INC | 1,500 0.00% of outstanding | $65k | Aug 22, 2025 | $5.9M |
| Aug 6, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 140,000 0.25% of outstanding | $5.3M | Aug 6, 2025 | none |
| Nov 8, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 125,000 0.23% of outstanding | $4.5M | Nov 8, 2024 | $4.6M |
| Nov 7, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 125,000 0.23% of outstanding | $4.6M | Nov 7, 2024 | none |
Transactions
The newest 50 of 104 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +29,849 | $0.00 | $0 | 1,270,993 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -12,642 | $46.57 | $589k | 1,258,351 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -29,849 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +29,849 | $0.00 | $0 | 29,849 | Jul 31, 2026 |
| Jun 17, 2026 | CGTX COGNITION THERAPEUTICS INC | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 73,500 | Jun 22, 2026 |
| Mar 13, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | JOther Common Stock10b5-1 | +12,500 | - | - | 1,241,144 | Mar 16, 2026 |
| Mar 13, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | JOther Common Stockindirect: By the KBT Trust10b5-1 | -12,500 | - | - | 993,100 | Mar 16, 2026 |
| Mar 13, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stockindirect: By the KBT Trust10b5-1 | -24,138 | $50.09 | $1.2M | 968,962 | Mar 16, 2026 |
| Mar 13, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stockindirect: By the KBT Trust10b5-1 | -10,742 | $51.00 | $548k | 958,220 | Mar 16, 2026 |
| Mar 13, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stockindirect: By the KBT Trust10b5-1 | -120 | $51.75 | $6,210 | 958,100 | Mar 16, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +38,640 | $0.00 | $0 | 1,245,218 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -16,574 | $54.73 | $907k | 1,228,644 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -38,640 | $0.00 | $0 | 0 | Mar 10, 2026 |
| Feb 28, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +38,640 | $0.00 | $0 | 38,640 | Mar 3, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +341,610 | $0.00 | $0 | 341,610 | Feb 20, 2026 |
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +81,250 | $25.30 | $2.1M | 1,266,478 | Oct 10, 2025 |
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -58,371 | $50.55 | $3.0M | 1,208,107 | Oct 10, 2025 |
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,529 | $51.46 | $79k | 1,206,578 | Oct 10, 2025 |
| Oct 9, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -81,250 | $0.00 | $0 | 0 | Oct 10, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | UTender of shares Common Stock | -5,000 | - | - | 0 | Oct 7, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -19,750 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,300 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Oct 7, 2025 | SCPH scPharmaceuticals Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -6,124 | $0.00 | $0 | 0 | Oct 7, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +2,267 | $25.30 | $57k | 1,163,137 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +20,000 | $0.00 | $0 | 1,181,233 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,904 | $48.06 | $92k | 1,161,233 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -7,796 | $46.21 | $360k | 1,173,437 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +19,320 | $0.00 | $0 | 1,192,757 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -2,267 | $0.00 | $0 | 81,250 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -7,529 | $46.21 | $348k | 1,185,228 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -20,000 | $0.00 | $0 | 0 | Oct 3, 2025 |
| Oct 2, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitsderivative | -19,320 | $0.00 | $0 | 0 | Oct 3, 2025 |
| Oct 1, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +53,785 | $25.30 | $1.4M | 1,201,043 | Oct 2, 2025 |
| Oct 1, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -40,173 | $48.07 | $1.9M | 1,160,870 | Oct 2, 2025 |
| Oct 1, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -53,785 | $0.00 | $0 | 83,517 | Oct 2, 2025 |
| Sep 30, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +11,510 | $25.30 | $291k | 1,155,846 | Oct 1, 2025 |
| Sep 30, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -8,588 | $48.25 | $414k | 1,147,258 | Oct 1, 2025 |
| Sep 30, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -11,510 | $0.00 | $0 | 137,302 | Oct 1, 2025 |
| Sep 29, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +13,688 | $25.30 | $346k | 1,154,571 | Sep 30, 2025 |
| Sep 29, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -10,235 | $48.02 | $491k | 1,144,336 | Sep 30, 2025 |
| Sep 29, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -13,688 | $0.00 | $0 | 148,812 | Sep 30, 2025 |
| Sep 23, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +47,940 | $12.98 | $622k | 1,170,396 | Sep 24, 2025 |
| Sep 23, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -29,513 | $47.23 | $1.4M | 1,140,883 | Sep 24, 2025 |
| Sep 23, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -47,940 | $0.00 | $0 | 0 | Sep 24, 2025 |
| Sep 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +27,060 | $12.98 | $351k | 1,139,043 | Sep 23, 2025 |
| Sep 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -16,587 | $47.02 | $780k | 1,122,456 | Sep 23, 2025 |
| Sep 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -27,060 | $0.00 | $0 | 47,940 | Sep 23, 2025 |
| Sep 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +20,000 | $0.00 | $0 | 20,000 | Sep 12, 2025 |
| Sep 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitsderivative | +19,320 | $0.00 | $0 | 19,320 | Sep 12, 2025 |
50 of 104 rows shown.
Questions about Jack A. Khattar
Answered from the filings on this page, as of the latest one.
Is Jack A. Khattar buying or selling?
In the last 12 months Jack A. Khattar reported 0 open-market buys worth $0 and 1 open-market sell worth $1.8M on SEC Form 4; the latest was sold $1.8M of SUPN on Mar 13, 2026. Grants, option exercises and tax withholding are not counted.
How did Jack A. Khattar's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jack A. Khattar has 0.
Where does Jack A. Khattar file Form 4?
Jack A. Khattar has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.) as President, CEO; CGTX (COGNITION THERAPEUTICS INC); SCPH (scPharmaceuticals Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.